Clinical Trial Update: AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AG followed by FOLFIRINOX with a PD-L1 antibody as conversion therapy for borderline resectable and locally advanced pancreati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• AG
• FOLFIRINOX
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• PD-L1 antibody

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Pancreatic Cancer | Phase 2 | Status: NOT_YET_RECRUITING